… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & CAMBRIDGE, Mass., … partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of Theresa …
… into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected by … loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s … of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas … ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and plans to …
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR’s first AI-discovered Development
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome